Tharimmune, Inc. — Director's Dealing 2022

Jan 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11

Reporting Person: Kharbanda Surender (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	721240	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options (right to purchase)	$7.822	2026-01-01	Common stock (946)		Direct

Footnotes

F1: The Registrant issued the Reporting Person the options on January 1, 2021. The options vested and became exercisable immediately upon grant.